Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluad in elderly subjects
NCT01152814Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2010
- Primary completion
- Jun 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of influenza vaccine (surface antigen, inactivated, adjuvanted) in seasonal influenza, sponsored by Novartis. Primary endpoints: Percentage of Participants Who Achieved Seroconversion or Significant Increase in Single Radial Hemolysis (SRH) Area Against Each of Three Vaccine Strains at Day 22, Geometric Mean Ratio of Participants Against Each of the Three Vaccine Strains at Day 22 and 1 more. Started Jun 2010; status: completed.
02
Drugs
influenza vaccine (surface antigen, inactivated, adjuvanted)
03
Conditions
seasonal influenza
Beyond the preview
Go deeper on NCT01152814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01152814.